Barclays
CLBT icon

Barclays’s Cellebrite CLBT Stock Holding History

Barclays’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$329K Sell
22,534
-27,564
-55% -$364K ﹤0.01% 3441
2026
Q1 		$690K Buy
50,098
+43,793
+695% +$660K ﹤0.01% 2983
2025
Q4 		$114K Buy
6,305
+3,582
+132% +$64.3K ﹤0.01% 4545
2025
Q3 		$50.5K Sell
2,723
-137,314
-98% -$2.16M ﹤0.01% 4765
2025
Q2 		$2.24M Sell
140,037
-13,987
-9% -$249K ﹤0.01% 2757
2025
Q1 		$2.99M Sell
154,024
-291,771
-65% -$6.14M ﹤0.01% 2325
2024
Q4 		$9.82M Buy
445,795
+182,138
+69% +$3.51M ﹤0.01% 1590
2024
Q3 		$4.44M Buy
263,657
+59,395
+29% +$881K ﹤0.01% 2190
2024
Q2 		$2.44M Sell
204,262
-99,740
-33% -$1.11M ﹤0.01% 2000
2024
Q1 		$3.37M Buy
304,002
+212,779
+233% +$2.17M ﹤0.01% 2131
2023
Q4 		$790K Buy
91,223
+75,615
+484% +$588K ﹤0.01% 3614
2023
Q3 		$119K Buy
15,608
+1,982
+15% +$14.9K ﹤0.01% 3531
2023
Q2 		$98.1K Buy
+13,626
New +$79.4K ﹤0.01% 3573

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Barclays's CLBT Position: Q2 2026 in Review

Barclays reduced its Cellebrite (CLBT) stake by 55% in Q2 2026, selling an estimated $364K and leaving 22,534 shares worth $329K. The position accounts for ﹤0.01% of the portfolio, ranked #3441.

Barclays first reported a position in CLBT in Q2 2023 and has held it in 13 quarters since. The position peaked at $9.82M in Q4 2024. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • Barclays held 22,534 shares of Cellebrite worth $329K as of Q2 2026.
  • Barclays sold 27,564 Cellebrite shares in Q2 2026, an estimated $364K.
  • Cellebrite made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3441 holding.
  • Barclays first reported a position in Cellebrite in Q2 2023 and has held it in 13 quarters since.
  • Barclays's Cellebrite position peaked at $9.82M in Q4 2024.
  • 201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.